Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.